Form 4: TriSalus Life Sciences Director Granted Stock Options

Arjun JJ Desai, a Director at TriSalus Life Sciences, Inc., was granted 15,000 stock options with an exercise price of $5.50 per share.

Summary

• Arjun JJ Desai, a Director of TriSalus Life Sciences, Inc. (TLSI), was granted 15,000 Director Stock Options on June 12, 2025.
• Each option grants the right to buy one share of common stock at an exercise price of $5.50.
• The options have an expiration date of June 11, 2035.
• The shares subject to the option will fully vest on the one-year anniversary of the grant date (June 12, 2025), or in any case, on the date of the Issuer's next annual stockholder meeting, subject to Mr. Desai's continued service.
• Following this transaction, Mr. Desai beneficially owns 65,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates continued alignment of a director's interests with the company's performance, which is generally viewed favorably by investors. It is a routine compensation event.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

The granted stock options are subject to a vesting schedule, which will see them fully vest on the one-year anniversary of the grant date (June 12, 2025) or at the Issuer's next annual stockholder meeting, contingent on the director's continued service.

Industry Context

The grant of stock options to directors is a common practice in the life sciences and broader corporate sectors, serving as a form of equity compensation to attract, retain, and incentivize key personnel by aligning their financial interests with company performance.

Stakeholder Impact

• Shareholders: The grant of options can lead to potential future dilution if exercised, but also signifies alignment of a director's interests with shareholder value creation.
• Employees: While this specific filing is for a director, equity compensation is a common tool across all levels of a company to incentivize performance.

Next Steps

• The granted options will vest according to the specified schedule, either on the one-year anniversary of the grant date or at the next annual stockholder meeting, subject to continued service.
• The director may choose to exercise the vested options at any time before their expiration date, subject to company policy and insider trading regulations.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Beneficial Ownership, Equity Compensation